Ultrasound Screening of the Aorta in Giant Cell Arteritis (GCA-PANIC)

GCA Panic - Giant Cell Arteritis: Predicting Aneurysms in Clinics

The goal of this observational study is to find out whether ultrasound can reliably detect dilatation and aneurysms of the aorta, the main blood vessel that carries blood from the heart to the rest of the body, in people with giant cell arteritis (GCA). GCA causes inflammation in the blood vessel walls. It can affect the aorta and increase the risk of aortic dilatation and aneurysms. Aortic dilatation is an abnormal widening of the aorta. When it becomes large, it is called an aneurysm, and can lead to serious complications.

The main questions the study aims to answer are:

How accurately can ultrasound performed by rheumatologists detect dilatation and aneurysms of the aorta compared with computed tomography (CT) angiography, which provides detailed images of the aorta?

How consistently do different rheumatologists evaluate the aorta using ultrasound?

How often is aortic dilatation and aneurysms found in people with GCA who previously had signs of inflammation in the aorta on a PET-CT scan?

Researchers will compare ultrasound measurements with CT angiography findings to assess how well ultrasound detects aortic dilatation and aneurysms.

The study will include 102 participants: 82 people with GCA and previous signs of aortic inflammation on PET-CT, 10 people with GCA and a known aortic dilatation or aneurysm, and 10 people with aortic dilatation or aneurysm not caused by inflammation.

Participants will undergo an ultrasound examination of the ascending aorta, the part of the aorta closest to the heart. Participants will also undergo CT angiography of the aorta, which uses X-rays and contrast dye to produce detailed images of the blood vessel. The ultrasound measurements will be compared with the CT angiography findings. The ultrasound evaluations of the ultrasound performing rheumatologists will be compared with evaluations of a blinded assessor.

The long-term aim is to determine whether ultrasound could be a useful, non-invasive screening method to help identify aortic dilatation and aneurysms in people with GCA.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

102

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

GCA patients will be recruited from the five Rheumatology clinics of the Region of Southern Denmark (Odense University Hospital, Svendborg Hospital, Esbjerg Hospital, the Danish Hospital for Rheumatic Diseases, Lillebælt Hospital). Non-GCA patients will be recruited from the Cardiology clinic of Esbjerg Hospital.

Description

Inclusion Criteria:

  • GCA diagnosis with initial PET-CT involvement of thoracic aorta for the "GCA without known dilatation or aneurysm of the aorta" cohort
  • Established ascending aortic dilatation or anerysm through CT or MR angiography of the aorta and a history of GCA for the "GCA with known dilatation or aneurysm of the aorta" cohort
  • Established ascending aortic dilatation or aneurysm through CT or MR angiography of the aorta and no history of vasculitis for the "Non-GCA with known dilatation or aneurysm of the aorta" cohort

Exclusion Criteria:

  • Inability to consent
  • Inability to undergo ultrasound of the aorta
  • BMI ≥ 40
  • Previous operation for aortic structural damage

Specifically for the "GCA without known dilatation or aneurysm of the aorta" cohort:

  • Inability to undergo CT angiography of the aorta
  • Unknown kidney function and unwillingness to have it tested before CT angiography
  • Known kidney failure (eGFR<30ml/min/1.73m3)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
GCA without known aortic dilatation or aneurysm but known aortic inflammation in PET-CT at debut

GCA patients with involvement of the thoracic aorta in the initial PET-CT upon diagnosis who have or have had regular follow-ups in the Rheumatology Clinics of the Region of Southern Denmark, who do not have known aortic dilatation or aneurysm, will be invited to participate in the study. These participants will undergo ultrasound of the proximal aorta and CT angiography of the aorta. Inclusion will stop at 82 subjects.

GCA with known aortic dilatation or aneurysm

GCA patients with CT or MR angiography-established dilatation or aneurysm of the thoracic aorta who have or have had regular follow-ups in the Rheumatology clinics of the Region of Southern Denmark will be invited to participate in the study. These participants will undergo ultrasound of the proximal aorta. Inclusion will stop at 10 subjects

Non-GCA with known aortic dilatation or aneurysm

Patients with CT or MR angiography established dilatation or aneurysm of the thoracic aorta on a non-inflammatory basis who have regular follow-ups in the Cardiology Clinic in Esbjerg Hospital will be invited to the study. These participants will undergo ultrasound of the proximal aorta. Inclusion will stop at 10 subjects.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic accuracy of thoracic aorta ultrasound for detecting aortic dilatation and aneurysms
Time Frame: At the baseline study visit.

The ability of ultrasound measurements of the thoracic aorta to identify aortic dilatation or aneurysms will be evaluated using CT angiography as the reference standard. A receiver operating characteristic (ROC) curve will be used to assess how well the ultrasound measurements distinguish between participants with and without aortic dilatation or aneurysms. Diagnostic performance will be summarized by calculating the area under the ROC curve (AUC).

At the baseline study visit.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Agreement between assessors in ultrasound measurements of the thoracic aorta
Time Frame: At the baseline study visit.

Agreement between rheumatologists performing ultrasound examinations and an independent, blinded assessor will be evaluated by comparing their measurements of the thoracic aorta. Agreement will be quantified using the intraclass correlation coefficient (ICC), which indicates how closely the measurements agree. A two-way random-effects model assessing absolute agreement will be used (ICC[2,1]).

At the baseline study visit.
Prevalence of thoracic aortic dilatation and aneurysm in GCA patients with prior FDG-PET/CT-confirmed aortic uptake
Time Frame: At the baseline study visit.

The prevalence of thoracic aortic dilatation and aneurysm will be assessed among the patients with giant cell arteritis (GCA) and aortic FDG uptake on PET/CT at diagnosis. Thoracic aortic diameters will be measured with CT angiography and aortic dilatation and aneurysm will be classified according to prespecified diameter-based diagnostic criteria. Prevalence will be calculated as the number of participants meeting the criteria for aortic dilatation or aneurysm at the study assessment divided by the total number of this cohort's participants with evaluable CT angiography scans. Aortic dilatation and aneurysm will also be reported separately, where applicable.

At the baseline study visit.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Stavros Chrysidis, MD PhD, University of Southern Denmark

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2027

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

November 3, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 115537

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.